In our study, we investigated the expression of FGFR2 and SPRY family in 104 gastric adenocarcinoma cases and evaluated their clinical significance, including correlations with clinicopathologic factors and prognostic value. This evidence concerns the gene FGFR2 and gastric adenocarcinoma.